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Scientific summary
Background
Glaucoma describes a group of chronic age-related eye diseases in which there is progressive damage of
the optic disc and characteristic visual field loss. Glaucoma is a significant public health problem, as it is the
second leading cause of blindness in the UK.
Glaucoma care constitutes a major proportion of the workload of the hospital eye service. In England there
are over 1 million glaucoma-related outpatient visits to the acute sector annually. Considerable NHS
resources are required to assess referrals to hospital eye services for possible glaucoma, which are typically
initiated by community optometrists. However, fewer than one-quarter of referrals are found to have
glaucoma, and nearly half of the referred individuals are discharged after their first visit. If referrals could be
triaged in a clinically effective and cost-effective manner, resources could be better utilised for other needs.
Glaucoma is diagnosed by clinicians detecting structural changes of the optic nerve head, also known as
the optic disc, and corresponding visual field defects. New imaging techniques for assessment of the
structural changes have emerged: scanning laser ophthalmoscopy, commercially available as the
Heidelberg Retinal Tomograph [HRT; including two diagnostic algorithms, Moorfields regression analysis
(HRT-MRA; Heidelberg Engineering, Heidelberg, Germany) and glaucoma probability score (HRT-GPS;
Heidelberg Engineering, Heidelberg, Germany)] and scanning laser polarimetry, commercially available as
glaucoma diagnostics (GDx; Carl Zeiss Meditec, Dublin, CA, USA) and spectral domain optical coherence
tomography (SD-OCT; Heidelberg Engineering, Heildelberg, Germany), with several commercial
devices available.
Imaging technologies are being introduced into glaucoma services but their role in the diagnostic pathway
is unclear. Imaging tests are user-friendly and safe, provide automated classifications and potentially could
reduce the need for an examination by a clinician.
Aim
To assess the relative performance and cost-effectiveness of diagnostic imaging technologies as triage tests
in secondary care for identifying people with glaucoma.
Objectives
Primary objective
To compare the diagnostic performance (in terms of sensitivity and specificity) in a cohort of patients
referred to hospital eye services with possible glaucoma, of:
l four imaging tests [HRT-MRA, HRT-GPS, GDx and optical coherence tomography (OCT)] for diagnosis
of glaucoma
l a composite triage test [combining imaging tests, visual acuity (VA) and intraocular pressure (IOP)
measurements] in correctly identifying patients to be discharged from secondary care.
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Secondary objectives
l To explore alternative thresholds for determining abnormal tests.
l To evaluate the diagnostic performance of combinations of imaging tests.
l To evaluate the performance of the tests across the spectrum of glaucoma (mild, moderate
and severe).
l To evaluate the cost-effectiveness of incorporating imaging in a triage test in hospital eye services
compared with current practice of diagnostic examination by a clinician.
l To evaluate patient preferences related to different imaging technologies.
Methods
We designed a pragmatic within-patient comparative diagnostic and triage evaluation of imaging
techniques for glaucoma. Participants were adult patients referred from community optometrists or general
practitioners with any possible glaucoma-related findings. Five UK NHS centres participated: three
academic centres and two district general hospitals.
Participants received all imaging tests: HRT-GPS, HRT-MRA, GDx and OCT. Possible tests results were
within normal limits, borderline or outside normal limits.
The HRT uses confocal laser scanning to allow quantitative structural measurement of the optic disc
anatomy. There are two main classification tools to relate measurements to normative data: (1) HRT-MRA,
which requires user definition of the optic disc boundary, and (2) HRT-GPS, which is fully automated.
The GDx scanning laser polarimeter measures the retinal nerve fibre layer (RNFL) thickness surrounding the
optic disc utilising the birefringent properties of the RNFL. The software provides a discriminating classifier
termed the nerve fibre indicator, which is fully automated.
Spectral domain OCT is an optical imaging technique providing high-resolution, cross-sectional imaging of
the retina analogous to B-scan ultrasonography but using light instead of sound. The Spectralis® optical
coherence tomograph (Heidelberg Engineering, Heidelberg, Germany) was used in this study.
The reference standard was a full clinical examination, including visual field testing, by a consultant
ophthalmologist with glaucoma expertise to determine (1) a diagnosis of glaucoma (mild, moderate or
severe) according to well-defined criteria (diagnosis analysis) and (2) whether or not the patient would be
discharged or should be monitored/treated within hospital eye services (triage analysis).
Statistical analysis
Sample size calculations were based on standard diagnostic accuracy study methods. A 5% significance
level based on a two-sided test was used, which required a study of 897 individuals to have 90% power
to detect an accuracy difference of 9% for the primary outcome of glaucoma diagnosis. Including a 6%
indeterminacy rate increased the sample size to 954.
Two diagnostic performance analyses were undertaken: a diagnosis and a triage analysis. For the diagnosis
analysis (classification of glaucoma), one eye per patient was used: the eye with more severe disease
except for in one sensitivity analysis. The test ‘abnormal’ definition was an imaging test result of ‘outside
normal limits’, with ‘borderline’ cases classified as ‘normal’. This was compared with a reference standard
diagnosis of ‘glaucoma’.
For the triage analysis, a composite test (including three components: imaging, IOP measurement and VA)
was compared with a reference standard of clinical decision ‘do not discharge’. The test categorised a patient
as needing evaluation by a clinician if any elements of the composite triage test were themselves ‘abnormal’
in either eye: imaging classification ‘outside normal limits’ or IOP> 21mmHg or VA of 6/12 or poorer.
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Primary diagnostic performance outcomes were the sensitivity and specificity of tests. Secondary diagnostic
performance outcomes were likelihood ratio and diagnostic odds ratio (DOR). The proportions of
indeterminate test results, low-quality imaging and need for pupil dilatation were measured and patient
preference for the tests was ranked. The test performance was assessed with respect to the glaucoma
spectrum (mild, moderate and severe), when including glaucoma suspects in the reference standard
diagnosis, and when including ‘borderline’ results as abnormal. The diagnostic performance of
combinations of tests was also evaluated.
Economic analysis
A current practice pathway model was developed whereby patients referred to hospital eye services were
seen by a nurse for VA assessment, a technician for visual field measurement and by a clinician.
In an alternative triage care pathway model, individuals were seen by a nurse for VA examination and
IOP measurement and a technician for imaging assessment. The triage test results classified patients as
needing referral for clinician diagnosis or as discharged. Those referred were seen by a technician for visual
field measurement and examined by a clinician.
The cost-effectiveness of four triage pathways, each using IOP, VA and one of the four imaging
technologies (which varied by their diagnostic ability and capital cost), and their subsequent care
management pathways was assessed using a multistate Markov model compared with current practice.
The cohort started in one of six health states: normal; at risk of glaucoma; mild glaucoma; moderate
glaucoma; severe glaucoma; or sight-impaired. The sensitivity and specificity of each triage strategy
determined if diagnosis was correct and, depending on this, the health state that patients would move
to and the associated progression of any underlying glaucoma.
Modelled care pathways were developed in consultation with the study team and the independent
steering committee and used our previous models in this area and reviewed guidelines, study data and
expert opinion.
Consequences were considered in terms of monetary costs (of testing and subsequent management of the
patient’s condition) to the NHS and in terms of the effects on quality of life (by assigning utility weights).
Combining these data with the probabilities of events occurring over time enabled costs, patient outcomes
and quality-adjusted life-years (QALYs) to be estimated for a hypothetical cohort of patients undergoing
each modelled strategy.
Model results were analysed as incremental cost per QALY and incorporated (1) costs (of testing) and triage
diagnostic outcomes, (2) costs (of testing and subsequent management) and (3) QALYs. The base-case
analysis used a cohort of 40-year-old males using prevalence data from the Glaucoma Automated Tests
Evaluation (GATE) study and for a 50-year time horizon. Cycle length was 1 year. The results were presented
in incremental cost-effectiveness ratios (ICERs).
Several deterministic sensitivity analyses were explored, which varied: the annual probability of discharged
patients having a sight test; the cost of triage tests; the start age of the cohort; the performance of the
diagnosing clinician; the diagnostic performance of imaging technologies; the prevalence of glaucoma in
the referred population; and utility weights for those ‘at risk of glaucoma’. The possibility of a hypothetical
pathway, in which patients diagnosed as ‘at risk of glaucoma’ were discharged from the service, was
explored to investigate the impact in terms of costs and QALYs.
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Results
Between April 2011 and July 2013, 2088 participants were identified as potentially eligible: 2013 were
invited to take part. Of those invited, 966 (48%) agreed to take part. Following consent, 11 participants
were found to be ineligible and did not participate and 12 were excluded as they did not receive all
four imaging tests. Therefore, 943 participants were available for the comparisons of tests.
The average age of participants was 60.5 years [standard deviation (SD) 13.8 years] and 51.1% were
female. Non-participants had similar age and sex balance. Most participants (89.2%) were of ‘white British’
ethnicity. The average IOP at referral was 20mmHg. The most common diagnosis was ‘no glaucoma-related
findings’ (31.7% of participants). Comorbidities were uncommon, except for cataract, which was reported
in 8.3% of right eyes and 7.4% of left eyes. Glaucoma was diagnosed in at least one eye in 16.8% of the
GATE cohort and 6.5% had glaucoma in both eyes at referral. Overall, 37.9% of GATE participants were
discharged after the first visit.
Performance of the imaging tests in diagnosing glaucoma differed. HRT-MRA had the highest sensitivity
[87.0%, 95% confidence interval (CI) 80.2% to 92.1%] but the lowest specificity (63.9%, 95% CI 60.2%
to 67.4%), GDx had the lowest sensitivity (35.1%, 95% CI 27.0% to 43.8%) but the highest specificity
(97.2%, 95% CI 95.6% to 98.3%) and the other two tests provided intermediate results (HRT-GPS
sensitivity 81.5%, 95% CI 73.9% to 87.6% and specificity 67.7%, 95% CI 64.2% to 71.2%;
OCT sensitivity 76.9%, 95% CI 69.2% to 83.4% and specificity 78.5%, 95% CI 75.4% to 81.4%).
Likelihood ratios showed evidence of being able to both rule in and rule out the presence of glaucoma for
all four imaging tests (95% CIs did not contain 1.0). DORs ranged from 9.24 for HRT-GPS to 18.48
for GDx.
When including borderline imaging results as an abnormal test, the sensitivity increased but with a
corresponding decrease in specificity. In this sensitivity analysis, HRT-MRA had the highest sensitivity
(94.9%, 95% CI 89.8% to 97.9%) but the second lowest specificity (43.9%, 95% CI 40.2% to 47.6%),
GDx had the lowest sensitivity (60.4%, 95% CI 51.6% to 68.8%) but the highest specificity (82.8%,
95% CI 79.8% to 85.5%) and the other two tests provided intermediate results.
The impact of combining two imaging tests was improved detection of glaucoma but the effect was
marginal and smaller than the loss of specificity.
When considering participants with severe glaucoma, according to our definition of disease stage,
OCT had the highest sensitivity (95.2%, 95% CI 76.2% to 99.9%) and the second highest specificity
(70.9%, 95% CI 67.7% to 73.9%), GDx had the lowest sensitivity (78.9%, 95% CI 54.4% to 93.9%)
but the highest specificity (93.7%, 95% CI 91.8% to 95.2%) and the other two tests provided
intermediate results.
The performance of triage tests (a composite assessment comprising imaging test, IOP and VA assessments)
in correctly identifying patients to be discharged from secondary care showed that triage including HRT-GPS
had the highest sensitivity (86.0%, 95% CI 82.8% to 88.7%) but the lowest specificity (39.1%, 95% CI
34.0% to 44.3%) and GDx had the lowest sensitivity (64.7%, 95% CI 60.7% to 68.7%) but the highest
specificity (53.6%, 95% CI 48.2% to 58.9%), the other two tests providing intermediate results [HRT-MRA
values were very similar to the HRT-GPS results in sensitivity (86.0%, 95% CI 82.8% to 88.7%) and
specificity (53.6%, 95% CI 48.2% to 58.9%) and OCT had lower sensitivity (75.4%, 95% CI 71.6% to
78.9%) but higher specificity (41.0%, 95% CI 35.8% to 46.3%) values than HRT-GPS and HRT-MRA].
Likelihood ratios (and 95% CI) showed evidence of all four triage tests being able to rule in and out the
presence of abnormalities for all four triage tests (CIs did not contain 1.0). DORs ranged from 2.1 for GDx
to 3.9 for HRT-GPS.
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Participant preference for type of imaging test was collected for 890 participants (94%). Almost half of
responders (48.2%) had no preference. Of those participants who expressed a preference, OCT was
ranked as most preferred (27.6%), followed by GDx (11.9%) and HRT (5.1%). Average time taken to
perform the test varied from 5.2 minutes (SD 3.0 minutes) for OCT to 7.6 minutes (SD 5.0 minutes)
for HRT.
Economic analysis results
All triage strategies were more cost-effective than current practice but resulted in reduced health because
of missing cases (i.e. fewer expected QALYs). The base-case results suggest that, of the triage pathways
modelled, a triage including IOP, VA and HRT-MRA is the most cost-effective strategy. Triage including
GDx was shown to be the least costly and least effective. Triage including OCT and HRT-GPS were not
cost-effective. Compared with GDx, the cost per QALY gained for HRT-MRA was £22,904. The cost per
QALY gained with current practice was £156,985 compared with HRT-MRA. Large savings could be made
by implementing HRT-MRA but some benefit to patients would be forgone.
These results should be interpreted with some caution, particularly in terms of differences among triage
strategies, since the diagnostic accuracy of all tests (except GDx) and their unit costs are very similar.
The incremental cost-effectiveness of the triage strategies compared with current practice is very sensitive
to the costs included in the model. Indeed, current practice becomes cost-effective when the total cost
of a triage test increases to £30 and above. A key assumption used in the model was that clinicians are
100% accurate in their diagnostic ability. Relaxing this assumption increased further the ICER (favouring
triage strategies).
Conclusions
Implications for health care
Imaging technologies can be effective to aid the diagnosis of glaucoma. An alternative pathway for
patients referred from community to hospital eye services with possible glaucoma, using a triage test that
includes imaging, IOP and VA, appears to be cost-effective compared with current practice. Our findings
are based on a relatively inexpensive composite triage test (< £30). The most cost-effective strategy would
include HRT-MRA imaging. However, triaging would be associated with a loss of health, and the
acceptability of this option among users and clinicians has not been evaluated.
Recommendations for research
l Determine the acceptability to patients and health-care providers of implementing an efficient triage
glaucoma diagnostic triage system but with reduced health.
l Obtain data on glaucoma disease progression, specifically including patients classified as having
glaucoma suspects and ocular hypertension, associated utility, and cost of providing health care.
l Investigate varying the results of the imaging tests beyond the standard options, since the
recommended classification may not be the one best suited to the population from which
GATE recruited.
l Examine the effectiveness of implementation of a composite triage test.
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